Sakamako daga babban gwaji na asibiti ya nuna cewa ƙara blinatumomab (Blincyto) zuwa maganin mutanen da ke fama da cutar. m lymphoblastic cutar sankarar bargo (ALL) wadanda suke cikin gafara, ko da babu alamun cutar, na iya taimaka musu su ci gaba da rayuwa.
A cikin binciken, ba da blinatumomab tare da chemotherapy ya sa mutanen da ke fama da ciwon daji da suka shiga cikin remission suna rayuwa da yawa fiye da wadanda kawai suka sami chemotherapy, wanda shine daidaitaccen magani na yanzu. Marasa lafiya a cikin gwaji ba kawai a cikin gafara ba, amma babu alamar ciwon daji. Wannan ake kira ciwon mafi ƙarancin saura cuta (MRD) - korau DUK.
An nuna sakamakon gwajin a taron shekara-shekara na Ƙungiyar Ciwon Jiki ta Amurka (ASH) a New Orleans a watan Disamba 2022.
In 2018, the Food and Drug Administration (FDA) cleared blinatummab to treat people with MRD-positive ALL who were in remission but still showed signs of cancer during follow-up tests. Even though recurrences after remission are always possible, people with MRD-positive ALL have a higher chance of their cancer coming back after their first treatment than those who do not have MRD.
A taron ASH, an nuna sakamakon ga mutanen da ba su samu ba MRD bayan maganin farko.
A cikin shekaru 3.5 bayan fara aikin farfadowa na baya-bayan nan, 83% na marasa lafiya da aka bi da su tare da blinatumomab da chemotherapy har yanzu suna raye, yayin da kawai 65% na marasa lafiya da aka yi amfani da su kawai suna da rai.
Blinatumomab yana da tasiri ga MRD-korau DUK kuma
B-cell ALL is the most common type of ALL in both adults and children. It is a type of cutar kansa that spreads quickly and is very dangerous. Chemotherapy is the standard treatment, and it often leads to remission. However, a lot of people get sick again, even if tests done after treatment show no signs of disease.
Magungunan rigakafi sun nuna wasu alkawuran a matsayin hanyar da za a magance ciwon daji bayan ya shiga cikin gafara kuma ya rage haɗarin dawowa.
Wani nau'in immunotherapy called a bispecific T-cell engager (BiTE) is what blinatumomab is. It sticks to both T cells and cancer cells at the same time. This makes it easy for T cells to find and kill the cancer cell by bringing them closer together. The drug, which is given through an IV, has been shown to be more effective than chemotherapy at treating B-ALL that has come back in children and young adults who have already been treated for it.
Wannan gwaji, wanda kungiyar ECOG-ACRIN Cancer Research Group ke gudanarwa tare da taimako daga NCI, an fara shi a cikin 2013 don ganin ko blinatumomab zai iya taimakawa mutanen da aka gano suna da B-cell ALL.
Ko da yake mutane 488 sun shiga cikin gwajin gaba ɗaya, sakamakon da aka nuna a ASH ya kasance ne kawai ga mutanen 224 waɗanda ke cikin remission da MRD-negative bayan tsarin farko na chemotherapy na farko. An ba marasa lafiya ko dai ƙarin chemotherapy ban da blinatumomab ko kuma kawai chemotherapy. Sa'an nan, duk da batutuwa sun sami chemotherapy kowane watanni shida na shekaru 2.5. Wasu kuma sun sami dashen kasusuwa idan likitansu ya ga ya fi kyau.
Ba wai kawai ƙara blinatummab zuwa chemotherapy ya inganta rayuwa gabaɗaya ba, har ma ya sa marasa lafiya su yi tsayin daka ba tare da ciwon kansa ya dawo ba idan aka kwatanta da waɗanda kawai suka sami chemotherapy.
Dr. Litzow ya ce babu daya daga cikin mutanen da suka sha blinatumomab da ke da illar da ba zato ba tsammani. Wasu daga cikin illolin blinatummab na yau da kullun sune zazzabi, martani ga jiko, ciwon kai, cututtuka, rawar jiki, da sanyi.
